Author: Peddapalli, Apparao; Gehani, Manish; Kalle, Arunasree M.; Peddapalli, Siva R.; Peter, Angela E.; Sharad, Shashwat
Title: Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review Cord-id: 8m0eoxj7 Document date: 2021_2_27
ID: 8m0eoxj7
Snippet: The immunological findings from autopsies, biopsies, and various studies in COVID-19 patients show that the major cause of morbidity and mortality in COVID-19 is excess immune response resulting in hyper-inflammation. With the objective to review various mechanisms of excess immune response in adult COVID-19 patients, Pubmed was searched for free full articles not related to therapeutics or co-morbid sub-groups, published in English until 27 October 2020, irrespective of type of article, country
Document: The immunological findings from autopsies, biopsies, and various studies in COVID-19 patients show that the major cause of morbidity and mortality in COVID-19 is excess immune response resulting in hyper-inflammation. With the objective to review various mechanisms of excess immune response in adult COVID-19 patients, Pubmed was searched for free full articles not related to therapeutics or co-morbid sub-groups, published in English until 27 October 2020, irrespective of type of article, country, or region. Joanna Briggs Institute’s design-specific checklists were used to assess the risk of bias. Out of 122 records screened for eligibility, 42 articles were included in the final review. The review found that eventually, most mechanisms result in cytokine excess and up-regulation of Nuclear Factor-κB (NF-κB) signaling as a common pathway of excess immune response. Molecules blocking NF-κB or targeting downstream effectors like Tumour Necrosis Factor α (TNFα) are either undergoing clinical trials or lack specificity and cause unwanted side effects. Neutralization of upstream histamine by histamine-conjugated normal human immunoglobulin has been demonstrated to inhibit the nuclear translocation of NF-κB, thereby preventing the release of pro-inflammatory cytokines Interleukin (IL) 1β, TNF-α, and IL-6 and IL-10 in a safer manner. The authors recommend repositioning it in COVID-19.
Search related documents:
Co phrase search for related documents- aberrant activation and activation syndrome: 1, 2, 3, 4
- aberrant activation and acute lung injury: 1, 2, 3, 4
- aberrant activation and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- aberrant activation and acute respiratory distress syndrome: 1, 2
- aberrant activation and adaptive immune response: 1, 2, 3, 4
- aberrant activation and lung damage: 1, 2, 3
- aberrant activation and lung disease: 1, 2, 3
- aberrant activation and lung infection: 1, 2
- aberrant activation and lung inflammation: 1
- aberrant activation and lung inflammatory: 1
- aberrant activation and lung injury: 1, 2, 3, 4, 5, 6, 7
- aberrant activation and lung macrophage: 1, 2
- aberrant activation and lung tissue: 1, 2, 3, 4
- aberrant activation and lupus erythematosus: 1
- aberrant activation and macrophage activation: 1, 2
- aberrant activation and macrophage activation syndrome: 1
- ability show and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9
- ability show and lung infection: 1
- ability show and lung tissue: 1
Co phrase search for related documents, hyperlinks ordered by date